Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian R Watson

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2021
Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus TreatmentTan-Trieu Nguyen, LeeAnn Ramsay, Mozhdeh Ahanfeshar-Adams, et al.
Mutation Research|July 7, 2005
Expression of p53 in renal carcinoma cells is independent of pVHLNatalie H Stickle, Lynn S Cheng, Ian R Watson, et al.
Pigment Cell & Melanoma Research|October 11, 2013
Why is melanoma so metastatic?Russell R Braeuer, Ian R Watson, Chang-Jiun Wu, et al.
The Journal of Experimental Medicine|December 5, 2025
Chimeric MHC class I- and II-restricted non-self epitopes broaden antitumor T cell reactionsRongsheng Zhang, Rong Ma, Merrin M L Leong, et al.
Oncogene|February 6, 2020
C3a elicits unique migratory responses in immature low-density neutrophilsBrian E Hsu, Joannie Roy, Jack Mouhanna, et al.
Nature Cancer|February 5, 2022
Multi-omic analysis reveals significantly mutated genes and DDX3X as a sex-specific tumor suppressor in cutaneous melanomaRached Alkallas, Mathieu Lajoie, Dan Moldoveanu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2016
MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMBApril A N Rose, Matthew G Annis, Dennie T Frederick, et al.
Molecular Cancer Therapeutics|October 22, 2020
Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase InhibitionTatiana Shorstova, Jie Su, Tiejun Zhao, et al.
Cancer Research|July 25, 2014
The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAFIan R Watson, Liren Li, Peter K Cabeceiras, et al.
Cell Reports|April 6, 2022
Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapyShivshankari Rajkumar, Diana Berry, Kayla A Heney, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2021
Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus TreatmentTan-Trieu Nguyen, LeeAnn Ramsay, Mozhdeh Ahanfeshar-Adams, et al.
Mutation Research|July 7, 2005
Expression of p53 in renal carcinoma cells is independent of pVHLNatalie H Stickle, Lynn S Cheng, Ian R Watson, et al.
Pigment Cell & Melanoma Research|October 11, 2013
Why is melanoma so metastatic?Russell R Braeuer, Ian R Watson, Chang-Jiun Wu, et al.
The Journal of Experimental Medicine|December 5, 2025
Chimeric MHC class I- and II-restricted non-self epitopes broaden antitumor T cell reactionsRongsheng Zhang, Rong Ma, Merrin M L Leong, et al.
Oncogene|February 6, 2020
C3a elicits unique migratory responses in immature low-density neutrophilsBrian E Hsu, Joannie Roy, Jack Mouhanna, et al.
Nature Cancer|February 5, 2022
Multi-omic analysis reveals significantly mutated genes and DDX3X as a sex-specific tumor suppressor in cutaneous melanomaRached Alkallas, Mathieu Lajoie, Dan Moldoveanu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2016
MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMBApril A N Rose, Matthew G Annis, Dennie T Frederick, et al.
Molecular Cancer Therapeutics|October 22, 2020
Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase InhibitionTatiana Shorstova, Jie Su, Tiejun Zhao, et al.
Cancer Research|July 25, 2014
The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAFIan R Watson, Liren Li, Peter K Cabeceiras, et al.
Cell Reports|April 6, 2022
Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapyShivshankari Rajkumar, Diana Berry, Kayla A Heney, et al.
Pageof 4